Guardian Molecule Keeps Cells On Track: New Perspectives For The Treatment Of Liver Cancer A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the German Cancer Research Center (DKFZ), the Hector Institute für Translational Brain Research (HITBR), and from the European Molecular Biology Laboratory (EMBL). The research is published in Nature Genetics. The discovery is of great interest for cancer medicine because a change of identity of cells has come into focus as a fundamental principle of carcinogenesis for several years. The Heidelberg researchers were able to show that the newly discovered sentinel is so powerful that it can slow down highly potent cancer drivers and cause malignant liver tumors to regress in mice. As a rule, the identity of cells is determined during embryonic development. They differentiate into nerve cells or liver cells, for example, and their fate is sealed. Only stem cells retain the ability to develop in different directions. However, once cells have differentiated, they usually stay on course. Deutsches Krebsforschungszentrum (DKFZ) Zentralinstitut für Seelische Gesundheit EMBL Events https://vist.ly/3n53ceh #liverhealth #livercancer #liverdisease (fb)

Older Age Predicts Worse Survival in Patients With HCC, Comorbidity Role Unclear In patients with hepatocellular carcinoma (HCC), worse survival is significantly associated with older age but not high comorbidity burden, according to study findings published in Clinical Gastroenterology and Hepatology. Previous research suggests HCC is a leading cause of cancer-related mortality worldwide, with patient outcomes closely tied to the stage of disease at diagnosis and access to curative therapies. While advanced age and comorbidities are known to predict worse cancer-related outcomes, their specific prognostic impact on HCC has not been well defined due to the competing risk of liver-related mortality. https://www.oncologynurseadvisor.com/news/older-age-predicts-worse-survival-in-patients-with-hcc-comorbidity-role-unclear/ #liverhealth #livercancer #liverdisease (fb)